Physician profile
Stephen P Smith
NPI 1588067706
$3,179.81
in general payments reported to CMS, 2019-2025
18 companies · $544 in 2025
The $544 reported for 2025 was more than what 79% of Optometrist providers received nationally (typical 2025 total: $204).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,077 · 2020: $30.39 · 2021: $334 · 2022: $223 · 2023: $219 · 2024: $753 · 2025: $544.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,515.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,515.43 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Bausch & Lomb Americas INC. | $401.99 | 2023-2024 | Miebo, Vyzulta, Xiidra |
| Alcon Vision LLC | $378.19 | 2019-2025 | Hydrus Microstent, Voyager Dslt |
| Bausch & Lomb, A Division of Bausch Health US, LLC | $344.11 | 2019-2021 | |
| Allergan, INC. | $237.58 | 2019-2021 | |
| Abbvie INC. | $237.41 | 2022-2023 | Vuity |
| Hoffmann-La Roche Limited | $211.31 | 2019 | |
| Oyster Point Pharma, INC. | $180.23 | 2022-2024 | Tyrvaya, Ryzumvi |
| Novartis Pharmaceuticals Corporation | $161.24 | 2019-2020 | |
| Sight Sciences, INC. | $148.74 | 2025 | Tearcare System |
| Shire North American Group INC | $123.34 | 2019 | |
| Kala Pharmaceuticals, INC. | $121.15 | 2021 | |
| Aerie Pharmaceuticals, INC. | $119.56 | 2019 | |
| Sun Pharmaceutical Industries INC. | $116.10 | 2024 | |
| Dompe US, INC. | $115.20 | 2025 | Oxervate |
| Johnson & Johnson Vision Care, INC. | $102.45 | 2019 |
Show all 18 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Tarsus Pharmaceuticals, INC. | $92.91 | 2024-2025 | Xdemvy |
| Amgen INC. | $69.51 | 2024 | Tepezza |
| Coopervision INC. | $18.79 | 2024 | Myday Contact Lens |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Stephen Smith listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.